close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

101.63 -0.05 (-0.05%)
Delayed Quote Updated: 2:16 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade ↗
Here's why Argenx could keep winning. 
Via The Motley Fool
News headline image
Halozyme (HALO) Q3 2026 Earnings Call Transcript ↗
Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) beat Wall Street’s revenue expectations in Q3 2026, with sales up 39.2% year on y... 
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO) Q3 In Line, Guidance Midpoint Below Consensus, Shares Fall After Hours ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO): An Undervalued Value Stock With Strong Profitability ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗
Via Chartmill
News headline image
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call ↗
Halozyme Therapeutics (NASDAQ:HALO) raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q3 2026, with revenue up 39.2% year on ... 
Via StockStory
News headline image
Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after market hours. Here’s what... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Reasons to Like HALO (and 1 Not So Much)
Halozyme Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 73.5%, reaching $120.69 per share. This w... 
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗
Via Chartmill
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock to Target This Week and 2 We Question
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
This biotech innovator could be in only the early chapters of its success story. 
Via The Motley Fool
News headline image
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
Topics Fraud
News headline image
3 Market-Beating Stocks for Long-Term Investors
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
Topics Economy
News headline image
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
Revenue jumped 48% to $481 million on record royalty growth. 
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance ... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on ... 
Via StockStory
News headline image
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Profitable Stock to Research Further and 2 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from... 
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.